Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)

The summary for the Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)
	CFDA Number:	93.855
	CFDA Description:	Allergy, Immunology and Transplantation Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health Income Security and Social Services
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PAS-10-148
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 22, 2010
	Creation Date:	Mar 22, 2010
	Original Closing Date for Applications:	May 07, 2013
	Current Closing Date for Applications:	May 07, 2013
	Archive Date:	Jun 07, 2013
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$650,000
	Federal Grant Award Ceiling:	$200,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models, including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for, primary immunodeficiency diseases. Investigators who have no prior history of receiving independent NIH funding or no prior history of receiving independent NIH funding in this field are encouraged to apply to this FOA. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-10-147, that encourages applications under the R03 small grant mechanism. Funds Available and Anticipated Number of Awards. It is anticipated that approximately $650,000 will be available under this FOA and that 2 new awards will be made each fiscal year. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pas-10-148.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Innovation for HIV Vaccine Discovery (R01); • NIAID Clinical Trial Implementation Cooperative Agreement (U01); • Therapeutics for Neurotropic Biodefense Toxins and Pathogens (R21/R33); • Strategies for the Protection of Pregnant Women and Infants Against Infectious Diseases (R01); • Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Inj...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers; • Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies: Project BioShield (R01); • Asthma and Allergic Diseases Cooperative Research Centers (U19)